Prime Medicine Administers First In Vivo Prime Editing Therapy for Wilson Disease

Key points

• On October 5, 2026, Prime Medicine announced the first patient in a Phase 1/2 trial received PM577a, an in vivo prime editing therapy targeting the H1069Q mutation in Wilson disease.
• The therapy uses lipid nanoparticles to deliver editing tools directly into the bloodstream, targeting liver cells to correct the ATP7B gene defect that causes copper accumulation.
• Unlike previous ex vivo approaches requiring cell extraction and chemotherapy, this method aims for a single infusion, potentially reducing production costs and treatment complexity.
• Preclinical studies in mice showed up to 80% editing efficiency and reduced copper accumulation, but human efficacy and safety remain unproven, with results expected in 2027.
• Experts highlight delivery precision as the core challenge, noting that ensuring the editing machinery reaches the correct cells without unintended changes is critical for success.

Background

This development follows earlier gene editing milestones, such as the December 2025 trial for chronic granulomatous disease using ex vivo editing. It also aligns with broader trends in gene therapy, including FDA approvals for ex vivo CRISPR treatments like Casgevy for blood disorders. The in vivo approach represents a significant shift from laboratory-based cell modification, aiming to make genetic therapies more accessible and scalable.

How outlets are covering it

Coverage across outlets emphasizes the milestone nature of in vivo editing but varies in focus. ZME Science and BioTecNika highlight the potential for a one-time cure and the technical advantages over ex vivo methods, while noting the experimental nature and safety concerns. CRISPR Medicine News provides a broader context, mentioning other in vivo trials like Beam Therapeutics' base editor for glycogen storage disease. Ground News notes the bias distribution, with 37% of sources leaning left and 36% right, reflecting diverse perspectives on the implications of gene editing technology. All sources agree on the significance of the trial but caution that results are pending.

Why it matters

This trial represents a potential paradigm shift in treating genetic diseases, moving from lifelong management to possible one-time cures. Success could reduce healthcare costs and improve quality of life for patients with rare diseases. However, challenges in delivery and safety must be addressed before widespread adoption. The outcome will influence future regulatory and clinical approaches to gene editing.

What to watch

Prime Medicine expects to announce first clinical results in 2027, assessing safety, copper metabolism, and potential discontinuation of existing medications. The FDA has granted PM577 Rare Pediatric Disease designation, indicating regulatory interest. Other companies are advancing similar in vivo therapies, such as Editas Medicine's LDL-cholesterol reduction trial in Australia. Monitoring these trials will be crucial for understanding the feasibility and safety of in vivo gene editing.